Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft - Drug Trials For Money - Paid Clinical Trials

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Conditions:   Allogeneic Hematopoietic Cell Transplantation (HCT);   Advanced Hematologic Malignancies;   Acute Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Disorders
Interventions:   Drug: Purified regulatory T-cells (Treg) plus CD34+ HSPC;   Drug: Fludarabine;   Drug: Melphalan;   Device: CliniMACS CD34 Reagent System;   Drug: Tacrolimus;   Drug: Cyclophosphamide;   Drug: Plerixafor;   Drug: Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent
Sponsors:   Stanford University;   Orca Biosystems, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 22, 2021 / by / in
Comments